

Review

Not peer-reviewed version

Migraine Treatment: Towards New Pharmacological Targets

[Marcello Silvestro](#)*, Luigi Francesco Iannone, Ilaria Orologio, Alessandro Tessitore, Gioacchino Tedeschi, Pierangelo Geppetti, [Antonio Russo](#)

Posted Date: 4 July 2023

doi: 10.20944/preprints202307.0175.v1

Keywords: CGRP; PACAP; VIP; adrenomedullin; amylin; KATP receptor; BKCa receptor; purinergic pathway; TRP channels; Glutamate



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Review

Migraine Treatment: Towards New Pharmacological Targets

Marcello Silvestro^{1,2,*§}, MD, Luigi Francesco Iannone³, MD, Ilaria Orologio¹, MD, Alessandro Tessitore^{1,2}, PhD, Gioacchino Tedeschi^{1,2}, MD, Pierangelo Geppetti³, PhD, Antonio Russo² and PhD

¹ Headache Centre, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Italy Russo¹

² Advanced MRI Neuroimaging Centre, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Italy

³ Headache Centre and Clinical Pharmacology Unit, Careggi University Hospital Florence, Italy.

* Correspondence: § Dott. Marcello Silvestro Headache Centre, Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", Naples; Ph/Fax +39-081-5665119; email: marcello.silvestro6@gmail.com.

Abstract: Migraine is a debilitating neurological condition affecting millions of people worldwide. Until few years ago; preventive migraine treatments were based on molecules with pleiotropic targets; developed for other indications and discovered by serendipity to be effective in migraine prevention although often burdened by tolerability issues leading to low adherence. However; the progresses in unravelling the migraine pathophysiology allowed to identify novel putative targets as calcitonin gene-related peptide (CGRP). Nevertheless; despite the revolution brought by CGRP monoclonal antibodies and gepants; a significant percentage of patients still remains burdened by an unsatisfactory response suggesting that other pathways may play a critical role with an extent of involvement varying among different migraine patients. Specifically; neuropeptides of the CGRP family as adrenomedullin and amylin; molecules of the secretin family as pituitary adenylate cyclase-activating peptide (PACAP) and vasoactive intestinal peptide (VIP), receptors as transient receptor potential (TRP) channels; intracellular downstream determinants as potassium channels but also the opioid system and the purinergic pathway have been suggested to be involved in migraine pathophysiology. The present review provides an overview of these pathways highlighting; based on preclinical and clinical evidences as well as provocative studies; their potential role as future targets for migraine preventive treatment.

Keywords: CGRP; PACAP; VIP; TRP channel; adrenomedullin; amylin; KATP receptor; BKCa receptor; purinergic pathway

1. Introduction

Migraine is a complex and debilitating neurological disorder affecting millions of people worldwide, ranked as the first cause of life lived with disability in young adults due to its considerable impact on personal well-being [1]. It is a chronic disease characterized by recurrent episodes of moderate to severe headaches accompanied by neurovegetative symptoms, such as nausea, vomiting, hypersensitivity to light, sound, and smell, as well as intolerance to physical activity [2]. The hallmark of migraine treatment is represented by approaches aimed to prevent future attacks based on lifestyle modifications, to avoid identified triggers or predisposing factors, as well as on preventive medications, to reduce the frequency and severity of migraine attacks [3]. Until five years ago, preventive migraine treatments were based on 'repositioning drugs,' molecules with different and pleiotropic targets, developed for other indications and discovered by serendipity to be rather effective in migraine prevention (i.e. β -blockers, antiepileptics drugs, antidepressants, and calcium channel antagonists) although burdened by tolerability issues leading to low treatment adherence [4]. However, the significant progresses in unravelling the pathophysiology of migraine attacks allowed the identification of putative specific targets for preventive migraine treatments such as calcitonin gene-related peptide (CGRP) pathway [5,6]. Indeed, the advent of CGRP-monoclonal antibodies (CGRP-mAbs), or more recently of gepants sets up, for the first time, a specific 'ad-hoc' approach against neuropeptides with a well-

known role in migraine pathophysiology, representing a turning point in migraine preventive treatment due to the high efficacy, safety and tolerability [7].

Nevertheless, despite the revolution brought by CGRP-mAbs and gepants in migraine armamentarium, a significant percentage of patients (close to 40%) still remains burdened by an unsatisfactory response suggesting that other molecules or pathways may play a critical role with an extent of involvement varying among different migraine patients or, possibly, migraine attacks [8,9]. Indeed, both preclinical observations and provocative studies have widely demonstrated that the administration of various neuropeptides, other than CGRP, is able to trigger migraine-like attacks in a non-neglectable percentage of patients [10]. These findings have spurred research towards the identification of new pharmacological targets in order to develop other specific drugs (See Figure 1 and Table 1 for further information).




Figure 1. Schematic and simplified graphical representation of the pathways involved in migraine pathophysiology that might represent future targets for preventive treatments. All the pathways, activated by the different molecules, converge in a common intracellular downstream determinant where the second messenger cAMP finally leads to the opening of KATP and BKCa channels. Abbreviations: AC, Adenylate Cyclase; AM, Adrenomedullin; AMP, Adenosine Monophosphate; AMY, Amylin; BKCa, Big Conductance Calcium-Activated Potassium Channel; ATP, Adenosine Triphosphate; cAMP, Cyclic Adenosine Monophosphate; CGRP, Calcitonin Gene-Related Peptide; CLR, calcitonin like receptor; CTR, calcitonin receptor; KATP, Adenosine Triphosphate-Sensitive Potassium Channel; Kir, inward rectifier K⁺ channel; PAC1,

Pituitary Adenylate Cyclase-Activating Polypeptide Type 1 Receptor; PACAP, Pituitary Adenylate Cyclase-Activating Polypeptide; PKA, Protein Kinase A; PDE3, phosphodiesterase 3; RAMP, receptor activity-modifying proteins; SUR, sulfonylurea receptor subunits; TRPA1, Transient Receptor Potential Ankyrin; TRPV, Transient Receptor Potential Vanilloid; VIP, Vasoactive Intestinal Polypeptide; VPAC, Vasoactive Intestinal Polypeptide Receptor.

Table 1. Overview of neuropeptides, receptors and ion-channels described to be involved in migraine pathophysiology (other than CGRP).

Neuropeptide/Receptor/Ion-channels	Chemical structure	Receptors	Extra-CNS action(s)	CNS action(s)	Action(s) in migraine	Provocative studies in HC	Provocative studies in migraine
PACAP	Polypeptide with 2 isoforms: • PACAP38 • PACAP27	PAC1 VPAC1 VPAC2 MrgX2	• Control of anterior pituitary hormone secretion • Vasodilation • Adrenaline and insulin secretion • Immunosuppression	• Regulation of neurotransmission • Neuroprotective effect in response to: - Cerebral brain ischemia - Traumatic brain injury - Spinal cord injury	• Dilation of dural and pial arteries • Mast cells degranulation	IV 20 min administration induces migraine-like attack in 17% of HC	IV 20 min administration induces migraine-like attack in 65-75% of pts
VIP	Polypeptide of 28 amino acids	VPAC1 VPAC2 PAC1	• Stimulation of gastrointestinal epithelial secretion and absorption • Stimulation of heart contractility • Vasodilation • Glycogenolysis • Anti-inflammatory and immune-modulatory	• Neurotrophic effects • Neurotransmission	• Opening of potassium channels • Dilation of dural and pial arteries	IV 25 min administration induces a marked vasodilation in the extracranial vessels and a very mild headache (42% of HC)	IV 2 h administration induces migraine-like attack in 71% of pts

Adrenomedullin	Polypeptide of 52/53 amino acids with 2 isoforms: • AM1 • AM2	AM1 receptor AM2 receptor	• Vasodilation • Bronchodilation • Regulation of diuresis • Regulation of food intake • Gastrointestinal modulation • Growth and hormone regulation • Anti-inflammatory effects	• Neuroprotective effect in response to: - Cerebral brain ischemia - Haemorrhagic stroke - Traumatic brain injury • Pain processing modulation	• Dilation of dural and pial arteries	NA	IV 20 min administration induces migraine-like attack in 55% of pts
Amylin	Polypeptide of 37 amino acids	AMY1 receptor AMY2 receptor AMY3 receptor	• Delay of gastric emptying • Reduction blood glucose by decreasing glucagon secretion	• Inhibition of food intake	• Pro-nociceptive action	NA	IV 20 min administration of amylin mimetic pramlintide induces migraine-like attack in 41% of pts
KATP channels	Octameric transmembrane protein complexes: 4 pore-forming Kir subunits and 4 SUR subunits	NA	• Regulation of insulin secretion • Control of vascular tone • Protection against metabolic stress	• Reduction in neurotransmitter release • Neuronal protection from excitatory toxicity • Analgesic and antinociceptive properties	• Dilation of dural arteries	IV 20 min administration of 0.05 mg/min levromakalim induces headache and MMA dilation reversed after sumatriptan 6 mg sc injection	IV 20 min administration of 0.05 mg/min levromakalim induces migraine attack in 100% of pts with MwA and 82% pts with MwA

BKCa channels	Octameric membrane protein complexes: 4 pore-forming subunits (α) and 4 accessory subunits (β)	NA	• Control of vascular tone • Regulation of cardiac rhythmicity • Modulation erectile and urinary autonomic functions • Regulation of gene expression and aging	• Regulation of neurotransmitter release • Modulation CBF • Neuroprotection • Modulate circadian rhythm	• Control of vascular tone of cranial arteries • Control of neuronal excitability	IV 20 min administration of 0.05 mg/min MaxiPost induces headache attacks (90% of HC)	IV 20 min administration of 0.05 mg/min MaxiPost induces migraine attacks in 100% patients with MwoA
Purinergic system	Adenosine ATP ADP	P1 (4) P2 - P2X (7) - P2Y (8)	• Cell proliferation • Cell death • Inflammation • Bone metabolism • Bladder contraction • Control of vascular tone • Coagulation	• Pain processing modulator • Neurotransmission • Neuromodulation	• Vasodilation • Neuronal sensitisation	NA	IV 20 min administration of 120 μ g/kg per minute adenosine induces headache attack in 78% of pts, no differences in migraine attack compared with placebo
δ -opioid receptors	GPCRs	NA	Regulation: • Emotional behaviours • Drug reinforcement • Inhibitory controls • Pain awareness and processing • Learning memory	• Regulation of acute pain threshold • Inhibition of the release of CGRP from trigeminal neurons	NA	NA	NA

κ -opioid receptors	GPCRs		NA	• Modulation of: • Reward • Mood states • Cognitive function	• Implication in: • Premonitory symptoms of a migraine • Stress induced allodynia	NA	NA
TRP channel	6TM cation channel	6 subfamilies: - TRPC (1-7) - TRPM (1-8) - TRPP (1-3) - TRPML (1-3) - TRPV (1-6) - TRPA	• Sensor of oxidative, nitrative and electrophilic stress • Vasoconstriction • Induction of vascular smooth muscle cell proliferation	• Contribute to the transmission and modulation of nociceptive signals • Detector of mechanical stimuli and noxious cold • Mediation of vision, taste, olfaction, hearing and touch	• Promotion of CGRP release • Mediator in neurogenic inflammation • Promotion of headache induced by toxic environmental irritants • Modulation of vascular tone of meningeal artery	NA	NA
Glutamate	α -amino-acid anion	Ionotropic receptors: - NMDA - AMPA - Kainate Metabotropic receptors (groups I-III)	NA	• Regulation of mood • Contribute to neuroplasticity including: - LTP - Regulation of spine density - Synaptic reorganization	• Primary role in CSD • Facilitation of neuronal activity within the TNC • Implication in peripheral and central neuronal sensitization	NA	NA

CNS: central nervous system; HC: healthy controls; PACAP: Pituitary Adenylate Cyclase-Activating Polypeptide; PAC1: Pituitary Adenylate Cyclase-Activating Polypeptide Type 1 Receptor; VPAC: Vasoactive Intestinal Polypeptide Receptor; IV: intravenous; min: minutes; pts: patients; VIP: Vasoactive Intestinal Polypeptide; h: hours; AM: Adrenomedullin;

NA: not applicable; AMY: Amylin; KATP: Adenosine Triphosphate-Sensitive Potassium Channel; Kir: inward rectifier K⁺ channel; SUR: sulfonylurea receptor subunits; mg: milligrams; MMA: middle meningeal artery; sc: subcutaneous; MwoA: migraine without aura; MwA: migraine with aura; BKCa: Big Conductance Calcium-Activated Potassium Channel; CBF: cerebral blood flow; ATP: Adenosine Triphosphate; µg/kg: micrograms/kilos; GPCRs: G protein-coupled receptor; CGRP: Calcitonin Gene-Related Peptide; TRP: Transient Receptor Potential; TM: transmembrane; TRPC: Transient Receptor Potential Canonical; TRPM: Transient Receptor Potential Melastatin; TRPP: Transient Receptor Potential Polycystin; TRPML: Transient Receptor Potential Mucolipin; TRPV: Transient Receptor Potential Vanilloid; TRPA: Transient Receptor Potential Ankyrin; NMDA: N-Methyl-D-aspartic acid; AMPA: α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; LTP: long term potentiation; CSD: cortical spreading depression; TNC: trigeminal nucleus caudalis.

In this review, we consider neuropeptides and pathways suggested by preclinical and clinical evidence as well as provocative studies to be involved in migraine pathophysiology, highlighting their role as potential future targets for migraine preventive treatment.

2. The vasoactive intestinal polypeptide (VIP)/glucagon/secretin family

The vasoactive intestinal polypeptide (VIP)/glucagon/secretin family is a group of related peptides including, among others, pituitary adenylate-cyclase-activating polypeptide (PACAP), , gastric inhibitory polypeptide (GIP), glucagon, and secretin [11]. The members of the VIP/glucagon/secretin family share sequence similarities and have overlapping functions in numerous physiological processes. They are involved in the regulation of metabolism, blood flow, immune responses, gastrointestinal functions, and neuronal signaling [11]. The role in migraine pathophysiology of two of them, PACAP and VIP, has been extensively studied.

2.1. PACAP

PACAP is a neuropeptide, firstly discovered in 1989, able to stimulate the production of cyclic adenosine monophosphate (cAMP) in the pituitary gland, hence its name [12]. In the last few decades, a growing body of scientific literature pointed out the role of PACAP in migraine pathophysiology [13]. PACAP can be found in two different isoforms with similar affinity and functions: PACAP38, representing approximately 90% of the total PACAP in mammalian tissues, and its truncated isoform, PACAP27 [14]. The PACAP38 segment 28-to-38, differentiating PACAP 38 from PACAP27, is recognized by the blood-brain barrier transporter to be transported into the brain tissues. PACAP38 half-life is of less than 5 minutes in human plasma *in vitro*, while the PACAP27 half-life is 45 minutes.

PACAP molecules exert their effects at four different receptors: PAC1, VPAC1, VPAC2, and the orphan MrgB3 receptor (in rodents) or MrgX2 receptor (in humans). VPAC1 and VPAC2 have equal affinity for PACAP38 and VIP ligands, while the PAC1 receptor has higher affinity (300 to 1000-fold higher) for PACAP38 than for VIP [15,16].

Similarly to CGRP, PACAP is involved in various biological functions, including neurotransmission, vasodilation, intestinal motility, cell proliferation, differentiation, neuroprotection, reproduction, and immunity [17]. Specifically, in the nervous system, PACAP38 acts as a hormone, a neurotransmitter, and a neuromodulator and its receptors are found in several important structures involved in pain perception and modulation as perivascular fibers, trigeminal and sphenopalatine ganglia, and the trigeminal nucleus caudalis [18]. In the trigeminal ganglion, besides neurons expressing only CGRP (about 68%) there are 32% of neurons expressing PACAP38 [19]. While the different PACAP receptors are widely expressed in the trigeminal ganglion and adjacent glial cells, VPAC1–2, but not PAC1, are expressed on intracranial arteries.

The role of PACAP38 in migraine pathophysiology is supported by increased plasma levels observed during spontaneous migraine attacks compared to the interictal phase, as well as by provocative studies [20,21]. The latter showed that intravenous administration of PACAP38 for 20-minutes can induce headache in healthy volunteers and delayed migraine-like attacks in 58–73% of patients with migraine without aura (MwoA), although the 20-minutes intravenous infusion of PACAP27 is able to provoke migraine-like attacks in the 55% of patients with migraine [22–25]. Interestingly, despite a provocation rate similar to CGRP, PACAP38-induced migraine attacks were more frequently accompanied by premonitory symptoms typically experienced by migraine patients (i.e. fatigue, yawning, neck stiffness, hunger or food cravings, mood swings, and poor concentration) but with a longer duration of flushing [25]. It could be hypothesized that the ability to enter the central nervous system (CNS) as well as the high concentration of PACAP38 and its receptors in the hypothalamus, known to be involved in the prodromal phase of the migraine cycle, could explain the higher incidence of premonitory symptoms administering PACAP38 compared to CGRP [26].

The PACAP38-induced migraine attacks are potentially mediated by its vasodilatory properties along with the meningeal mast cells degranulation [13,23]. Although there are still not converging evidences about the PACAP38 receptor able to mediate vasodilation, VPAC1–2 receptors are the most

likely involved considering that PAC1 receptor antagonist is unable to inhibit PACAP38 induced vasodilation in “in vivo” studies [27].

Interestingly, after intravenous PACAP38, a prolonged dilatation has been observed only in extracranial and meningeal arteries but not in cerebral arteries, probably because, in spite of the described transport mechanism, PACAP38 is only minimally able to pass the blood-brain barrier (0.053%) [28]. Therefore, it can be argued that PACAP site of action is mainly outside of the blood-brain barrier and most probably associated with vasodilation of the meningeal arteries. The role of vasodilation in PACAP38-induced migraine attacks seems to be further enforced by the ability of sumatriptan, a well-known anti-migraine drug with vasoconstrictor properties, to prevent PACAP38-induced migraine attacks (induction rate 15% after sumatriptan vs 42% after placebo) [29]. Nevertheless, the pre-treatment with sumatriptan (but not ketorolac) is able to prevent PACAP38-induced migraine attacks without affecting PACAP38-induced arterial dilation, while post-treatment with ketorolac, but not sumatriptan, attenuated PACAP38-induced headache [30]. These findings suggest that PACAP38-induced headache in healthy volunteers can be attenuated by sumatriptan independently from vasoconstriction, with time dependent preventative effects probably inhibiting central sensitization by blocking peripheral signal transmission from the meningeal nociceptors [30]. Similarly, since ketorolac antinociceptive effects may depend, at least partially, by the inhibition of inflammatory mediators released by mast-cells (without acting on arterial dilation), the pronounced skin flushing (alleviated by anti-histaminergic drugs) may be underpinned by mast-cells degranulation induced by intravenous infusions of PACAP38 in humans [31]. However, a recent study has downsized the role of mast cell degranulation in PACAP38-induced migraine-like attacks reporting that pretreatment with H1-antihistamine and clemastine (anticholinergic drug) was unable to prevent attacks [32]. Similarly, no change in peripheral plasma levels of inflammatory mast cell mediator tryptase was observed after PACAP38 infusion in patients with MwoA [33]. However, it cannot be excluded that the timing and the site of collection might play a role in detecting altered plasma levels of mediators of mast-cell degranulation and it is unknown whether peripheral plasma may reliably reflect cranial release of mast-cell mediators and, in turns, mast-cell degranulation cannot be completely dismissed as a mediator of PACAP38-induced migraine attacks [34,35].

Also considering the mast-cell degranulating effect of PACAP38, the mainly involved receptors are matter of debate. Indeed, if on one hand preclinical evidence failed to demonstrate the role of PAC1 receptors in mast-cell degranulation, on the other hand the MrgB3 receptor, corresponding in humans to MRGX2 receptor, seems to have a role, in particular in the long-lasting flushing and in delayed migraine attacks observed after PACAP38 infusion in humans [36].

Independently from the role of vasodilation and mast-cell degranulation in the PACAP38-induced migraine attacks and the specific receptor involved, there are compelling preclinical evidence suggesting that PACAP38 pathway is different from other migraine-provoking pathways [37,38]. Indeed, against the old hypothesis that PACAP and CGRP pathways are converging through the cAMP in the opening of adenosine triphosphate-sensitive potassium (KATP) channels, recent observation support that PACAP38-induced hypersensitivity is not mediated via an increase in CGRP release, clearly highlight PACAP38 pathway as distinct from other migraine-provoking pathways, such as CGRP and glyceryl trinitrate (the latter well-known as a CGRP-related) migraine trigger. For instance, a study on mice with genetically modified CGRP receptors (receptor activity-modifying proteins-1 knockout) showed that PACAP38 induced hind paw hypersensitivity and carotid artery vasodilation in receptor activity-modifying proteins-1 knockout mice, as well as in mice pre-treated with monoclonal antibody against CGRP. Similarly, monoclonal antibodies against PACAP38 did not improve CGRP-induced light aversion (as a surrogate for migraine-like photophobia) in mice, whereas CGRP-mAbs did not block light aversion induced by infusion of PACAP38 [39]. Therefore, PACAP antagonism has been clearly identified as a novel therapeutic target, and therefore, specifically considering preliminary provocation studies showing that the infusion of PACAP but not of VIP was able to induce migraine-like attacks, the attention was primarily focused on PAC-1 receptor (characterized by an extremely higher affinity for the PACAP

compared to the VIP unlike the VPAC1 and VPAC2 receptors) [40]. Surprisingly, monoclonal antibodies targeting the PAC1 receptor failed to demonstrate therapeutic benefits in a phase 2 randomized study controlled with placebo [41]. On the other hand, since PACAP38 exerts its activity on other receptors in addition to PAC1, it cannot be excluded that monoclonal antibodies targeting PACAP ligand may be more beneficial as migraine preventive strategy and there are anti-PACAP monoclonal antibodies targeting the ligand under development (i.e. LY 3451838, Lu AG09222), to date [42]. Very recently, a randomized, double-blind, parallel-group, single-dose, placebo controlled study demonstrated that Lu AG09222 reduced headache in healthy controls and inhibited concomitant cephalic vasodilation and increased heart rate induced by PACAP38 [43]. Even though some may be concerned about PACAP therapies side effects due to its multiple functions, no considerable adverse effects were reported in phase I and II clinical trials.

2.2. VIP

VIP is a member of the VIP/secretin/glucagon superfamily of peptides structurally connected to PACAP, that serves various functions in the body. Its primary role is vasodilation, occurring in both systemic circulation and specific tissues, including the respiratory system, gastrointestinal tract, and the central and peripheral nervous systems [44]. However, it is involved in the regulation of different physiological processes, such as smooth muscle contraction, glandular secretion, immune responses, and inflammation [44]. Apart from its vasodilatory function, VIP also acts as a neurotransmitter and neuromodulator in cerebral parasympathetic perivascular nerve fibers and cranial parasympathetic ganglia [45]. The biological effects of VIP are mediated via VPAC1 and VPAC2 receptors and, to a much lesser extent, PAC1 receptors. VIP and its receptors are expressed in smooth muscle cells, neurons and glial cells of trigeminal and sphenopalatine ganglia, and trigeminal nucleus caudalis [46]. VIP can only cross the blood-brain barrier to a very small extent. The putative role of VIP in migraine pathophysiology is still debated: on one hand, elevated VIP plasma levels have been reported in the cranial circulation of migraine patients with pronounced autonomic symptoms in the course of migraine attacks but also in chronic migraine patients during the interictal period when compared to both episodic migraine patients and healthy controls [47]. On the other hand, provocation studies with a 20-minute infusion of VIP resulted in a short-lasting dilation of the superficial temporal and middle meningeal arteries in the absence of headache, in both healthy controls and patients with migraine [23,48,49]. VIP is the first substance that markedly dilates intra- and extracranial arteries, nevertheless, it does not induce migraine, further weakening the hypothesis of a purely vascular origin of migraine. However, more recently, a model of prolonged infusion of VIP (e.g. 2-hour) has been proven to cause long-lasting dilation of the superficial temporal artery and delayed headache in both healthy volunteers and patients with migraine [50,51]. More specifically, a randomized, double-blind, placebo-controlled, 2-way crossover study demonstrated that 2-hour VIP infusion induced the ignition of a migraine attack in 71% of patients compared with only 5% after placebo administration. It is noteworthy that, despite CGRP plasma levels elevation following prolonged VIP infusion, no correlation was found between CGRP levels and the occurrence of VIP-induced migraine-like attacks, supporting that VIP-induced migraine-like attacks are not mediated by CGRP release [52].

However, it remains to be delineated the receptors that specifically mediate VIP-induced vasodilation. Vasoactive peptides are able to activate receptors expressed on smooth muscle cells and upregulate intracellular cAMP, initiating a signalling cascade resulting in the opening of potassium channels and, in turns, vasodilation. It is unlikely that VIP-induced migraine-like attacks are mediated via PAC1 due to 1) the very low affinity of VIP for PAC1 receptor and 2) their debated presence in the cranial vasculature (while PAC1 receptors are expressed in the trigeminal and sphenopalatine ganglia as well as the spinal trigeminal nucleus).

As proof of concept, maxadilan, a selective PAC1 receptor agonist, did not show vasodilator effects in intracranial and extracranial rat arteries [53]. Therefore, dilation of cranial arteries induced by VIP and PACAP is thought to be predominantly mediated by the prolonged stimulation of VPAC1

and VPAC2 receptors, leading to the opening of KATP channels or big-conductance calcium-activated potassium (BKCa) channels in the extracranial meningeal vasculature [54]. Whether prolonged extracranial artery dilation alone can explain VIP-induced migraine-like attacks or whether other mechanisms should be invoked is questionable to date. It cannot be excluded that VIP-induced migraine-like attacks may be at least partially mediated via mast-cells-related neurogenic inflammation although a recent study conducted in sympathectomized rats, an experimental preclinical model of migraine, showed a modulating role of VIP in mast-cell behaviour [55]. More in depth, VIP is able to decrease both mast cells and c-Fos expression in the trigeminal nucleus efficiently modulating neurogenic inflammation of the dura by reducing the number of local mast-cells induced by sympathectomy.

Altogether these data, along with the failure of a monoclonal antibody targeting the PAC1 receptor (AMG 301) in migraine prevention, arise some questions about the role of PAC1 receptor in the ignition of migraine-like attacks after both PACAP38 and VIP intravenous infusion, strongly suggesting the momentous role of VPAC1 and VPAC2 receptors as possible targets.

3. The calcitonin/CGRP family

The calcitonin/ CGRP family is a group of peptides sharing structural similarities including calcitonin, CGRP, amylin, and adrenomedullin [56]. Beyond CGRP, both amylin and adrenomedullin have been extensively investigated to ascertain their involvement in migraine pathophysiology. Receptors for calcitonin peptide family consist of two G protein-coupled receptors as the calcitonin receptor (CTR), and the calcitonin like receptor (CLR), together with an accessory receptor activity-modifying proteins (RAMPs) [57]. These protein-protein interactions enable receptors with variable affinity for different combinations of calcitonin-family peptides.

3.1. Adrenomedullin

Adrenomedullin is a multifunctional endothelial peptide hormone first isolated in 1993 from the adrenal medulla, hence its name [58]. It exists in two different isoforms with almost overlapping affinity and functions: AM1, a 52-amino acid peptide, and AM2, a 53-amino acid peptide. Both isoforms are expressed at high concentrations by vascular endothelial cells, smooth muscle cells, and immune cells [59]. Adrenomedullin is widely distributed throughout the body and participates in various physiological processes, including vasodilation, bronchodilation, fluid homeostasis, angiogenesis, immune response, and hormone regulation [59]. Due to its diverse functions and widespread distribution, adrenomedullin has attracted considerable attention as a potential therapeutic target for several disorders, such as hypertension, retinopathy, and tumorigenesis.

The strong molecular relationship with CGRP suggests a role of adrenomedullin in migraine pathophysiology, likely mediated by its effects on vasodilation, neurogenic inflammation and pain perception and transmission [60].

Preclinical studies have shown that administration of adrenomedullin induces dilation of dural and pial arteries, reduces mean arterial blood pressure, and increases local cerebral blood flow [61]. However, these effects are inhibited by canonical CGRP-receptor antagonists. Nevertheless, nitric oxide and cAMP are involved in adrenomedullin-induced vasodilation, further implicating its role in migraine-related vasodilation [62]. Adrenomedullin exerts a proinflammatory but also an anti-inflammatory effect by inhibiting the production and release of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF- α) and interleukin-6 (IL-6), in various preclinical experimental models [63]. Furthermore, if on one hand adrenomedullin is reported to have pro-nociceptive functions, on the other hand it modulates pain processing at various levels, including the spinal cord and the trigeminal system [64]. Specifically, experimental preclinical investigations showed that the intrathecal administration of adrenomedullin can induce thermal hyperalgesia and mechanical allodynia in the rat formalin test [65,66]. Interestingly, mouse model knockout for adrenomedullin showed longer latency in the tail-flick test, measuring the spinal reflexes, and shorter latencies in the hotplate test, requiring encephalic processing, suggesting that adrenomedullin acts as a nociceptive

modulator in spinal reflexes but has analgesic function at higher cognitive levels [67]. However, no studies have explored adrenomedullin-induced non-nociceptive migraine-like responses (e.g. light aversion).

Interestingly, while intravenous infusion of adrenomedullin did not cause headache attacks in healthy subjects, conflicting results were observed in patients with MwoA [68–70]. In a first crossover double-blind study conducted on 12 patients, no differences were observed in the percentage of patients reporting headache attacks, as well as in cerebral blood flow, following adrenomedullin or placebo administration [68]. However, the placebo migraine response rate in this study (33.3%) was significantly higher than the average placebo response rate in migraine provocation studies and may have therefore confounded the interpretation of results [69]. Nevertheless, a more recent study conducted on a larger sample of 20 patients using the same protocol showed a significantly higher percentage of headache attacks when patients were exposed to adrenomedullin compared to placebo (55% vs. 15%) but common and expected adverse events associated with adrenomedullin infusion (e.g. increased heart rate, palpitations, facial flushing, and heat sensations) may have unblinded the study [70].

It is also possible that adrenomedullin administration may act through the canonical CGRP receptor, as the estimated blood concentrations reached in these studies would likely activate, in addition to the AM1 and AM2 receptors, also CGRP receptor [71]. Notably, adrenomedullin-induced migraine-like attacks were similar in terms of time to onset and pain distribution to CGRP-induced migraine-like attacks. To clarify whether the canonical CGRP receptor mediates the response to adrenomedullin, further evaluation could be done to determine if a gepant, an antagonist of the CGRP receptor with very low affinity for AM receptors, is able to inhibit AM-induced migraine-like attacks. In conclusion, unlike the other neuropeptides, the involvement and the role of adrenomedullin in migraine attacks are less clear and needs further investigation before a clear-cut definition as a promising target in migraine pharmacological management.

3.2. Amylin

Amylin is a 37-amino acid peptide that belongs to the CGRP peptide family, sharing significant amino acid sequence identity with CGRP [72]. This neuroendocrine hormone is secreted alongside insulin from pancreatic β -cells in response to food intake. It acts in the brain to promote satiation, signalling the end of a meal, and lowers blood glucose levels by decreasing glucagon secretion [73]. Pramlintide, an amylin mimetic, is an approved drug for the treatment of insulin-requiring diabetes and has also been studied as a potential treatment for obesity in clinical trials [74].

Amylin expression extends beyond pancreatic cells and can be found in the dorsal root ganglia, as well as neurons of the trigeminal ganglia [75]. However, antibodies used to detect amylin in the trigeminal ganglia also recognize CGRP due to the high sequence similarities between these two neuropeptides. Amylin binds to at least three distinct receptors with high affinity: AMY1, AMY2, and AMY3 [56]. These receptors consist of core CTR in combination with one among RAMP1, RAMP2, or RAMP3. Interestingly, the AMY1 receptor, which contains the RAMP1 subunit, can also be activated by CGRP [56,57]. However, while amylin is potent at the amylin receptor, it has weak activation at the CGRP receptor, contrariwise CGRP activates both receptors with similar potency. Notably, medications like gepants and erenumab effectively antagonize the CGRP receptor and the AMY1 receptor and that is the mechanism proposed to explain differences in adverse effects between monoclonal antibodies targeting the CGRP ligand versus the CGRP receptor and to provide a rationale for observed differences when switching between these molecules [76].

The potential role of amylin in pain has been explored in preclinical studies, which indicate that amylin can induce pro-nociceptive and migraine-like behaviours in rodents. For example, mice knock-out for amylin showed reduced nociceptive behaviours in response to chemical pain stimuli (formalin injections) while amylin in female mice (but not males) decreases mechanical pain thresholds, increases light aversion, and induces squint response while reduce thermal threshold via intracerebroventricular injection [77–79]. The pain behaviour following amylin was consistently

reversed when amylin antagonists such as AC187 and rat Amy8–37 were administered [80,81]. Therefore, it can be argued that the effects of amylin strongly depend on factors such as gender, route of administration, or specific nociceptive pathways investigated.

Contrariwise, studies examining amylin in primary headache disorders suggest a potential pronociceptive role. Elevated levels of circulating amylin have been found in patients with chronic and, to a lesser extent, episodic migraine, independent of metabolic status and obesity, suggesting a significant role in migraine pathophysiology [82]. Indeed, a double-blind crossover study demonstrated that the percentage of patients with migraine reporting headache attacks or migraine-like attacks after pramlintide infusion was not significantly different from CGRP infusion [83]. Specifically, pramlintide was able to induce headache in 88% of patients and a migraine-like attack in 41% of patients (compared with 97% and 56% respectively with CGRP infusion). Pramlintide, like amylin, is a weak agonist of the canonical CGRP receptor (CLR/RAMP1), with even less activity at the adrenomedullin receptors. This suggests that the CTR/RAMP complexes, particularly AMY1, mediate pramlintide-induced migraine-like attacks. Interestingly, some patients respond only to CGRP, while others respond only to pramlintide. Similarly, pramlintide administration did not elevate circulating CGRP levels, and the peak plasma concentration of pramlintide was insufficient to activate the CGRP receptor, indicating that pramlintide-induced migraine-like attacks are likely independent of the involvement of CGRP pathway. Although the understanding of amylin's functions and its potential contribution to migraines and pain disorders is still evolving, altogether these findings tend to highlight the possibility of different involvement of CGRP and amylin pathways among different migraine patients, providing a rationale for the development of molecules that selectively target amylin pathway.

4. Potassium channels

Targeting each signalling pathway separately has proven to be only partially successful, suggesting that a common downstream determinant may represent a new target potentially able to revolutionize the migraine preventive treatment. In this context, it is noteworthy that the pathways of CGRP, PACAP, adrenomedullin, amylin but also nitric oxide converge to increase cAMP or cyclic guanosine monophosphate (cGMP) levels leading to the final opening of KATP or BKCa channels with consequent cellular potassium efflux and, in turns, membrane hyperpolarization and tissue specific cellular response.

4.1. KATP channel

KATP channels are large hetero-octameric transmembrane protein complexes constituted by four pore-forming inward rectifier K⁺ channel subunits (e.g. either Kir6.1 or Kir6.2) and four regulatory sulfonylurea receptor subunits (e.g. SUR1, SUR2A, or SUR2B) [84]. Firstly described in cardiac muscle cells, KATP channels are also found in the pancreas, skeletal muscle cells, smooth muscle cells, and nervous system [85]. KATP channels are characterized by structural and functional diversity determined by distinct combinations of Kir and SUR subunits. Kir6.2/SUR1 KATP channels are expressed in pancreatic β -cells, peripheral nervous system (e.g. trigeminal ganglia) and CNS (e.g. trigeminal nucleus caudalis), while Kir6.2/SUR2A subtypes are exclusively found in cardiac cells [86]. However, the most relevant in migraine pathophysiology seems to be Kir6.1/SUR2B constituting the major KATP channel in vascular smooth muscle cells as well as in trigeminal ganglia and in trigeminal nucleus caudalis. The KATP channels are activated by Mg²⁺-bound nucleotides and adenosine diphosphate (ADP, which act on the SUR subunit, and inhibited upon binding of intracellular ATP to the Kir6 subunit. Thus, KATP channels are open during states of low metabolic activity (e.g. low levels of ATP/high levels of ADP) resulting in plasma membrane hyperpolarization [87]. The ability to couple cellular metabolic state (ATP/ADP ratio) to the electrical activity of the cell membrane is critical in numerous physiological processes and is a key feature of KATP channels [88].

Several KATP channel openers (such as nicorandil, minoxidil, pinacidil, and diazoxide) are used in clinical practice due to vasodilating effects in angina and hypertension as well as alopecia although

burdened by headache, one of the most reported side effect due to the fact that KATP channels (particularly Kir6.1/SUR2B subtypes) are also expressed in the middle meningeal artery [89].

Moreover, while intravenous administration of levromakalim, a KATP channel opener, induces headache and middle meningeal artery dilation in healthy volunteers, reversed by sumatriptan injection, it provokes migraine-like attacks in 100% of patients with migraine and migraine with aura attacks in the 59% of patients with migraine with aura [90,91]. These observations led to investigations on blockage of KATP channels by glibenclamide (a nonspecific KATP channel blocker belonging to the second generation of sulfonylurea used in diabetes mellitus) in order to ascertain its reliability as a putative approach for migraine prevention [92,93]. Actually, although the efficacy of glibenclamide in reversing the vasodilation related to CGRP, PACAP, or prostacyclin and inhibiting cutaneous hypersensitivity in female mice injected with levromakalim or glyceryl trinitrate was demonstrated in preclinical studies, it failed to prevent headache attacks induced by levromakalim, PACAP38, or CGRP in humans, being only able to delay the onset of levromakalim-induced headache [93–95]. It could be argued that headache attacks are mediated by the activation of specific isoforms of KATP channels sulfonylurea receptor subunits, and KATP blockers more selective than glibenclamide are needed to further elucidate the role of potassium channels in migraine pathophysiological mechanisms. For instance, the SUR2B subunit, widely expressed in the trigeminovascular system, may represent a valuable future therapeutic target for migraine treatment.

4.2. BKCa

BKCa channels are octameric membrane protein complexes consisting of four pore-forming subunits (α) associated with four accessory subunits (β) regulating channel gating behavior [96]. Four distinct β -subunits ($\beta 1$ – $\beta 4$) have been discovered. The $\beta 2$ and $\beta 3$ subunits share sequence similarities with $\beta 1$, but unlike $\beta 1$ and $\beta 4$, which favour the active conformation, $\beta 2$ and $\beta 3$ promote a fast-inactive conformation in BKCa channels [97]. The $\beta 1$ subunit is primarily expressed in smooth muscle and some neurons of trigeminal ganglion and trigeminal nucleus caudalis, while the $\beta 4$ subunit is highly expressed in the whole brain [98,99].

BKCa channel openers such as andolast and cilostazol have been investigated for the treatment of bronchial asthma and intermittent claudication, respectively and both were associated with frequent adverse events, including headache [87]. Specifically, cilostazol is known to induce headaches in healthy volunteers as well as migraine-like attacks in patients with migraine [100,101]. To confirm the role of BKCa channels in migraine pathophysiology, MaxiPost, a positive modulator of BKCa channels, with high lipophilic properties facilitating its crossing of the blood-brain barrier, has been used to systematically explore headache following BKCa channel activation [100,101]. Specifically provocative studies have shown that 20-minutes continuous intravenous administration of 0.05 mg/min MaxiPost induced headache attacks in 90% of healthy controls and in 100% of patients with MwoA [100,101]. Interestingly, 95% of patients with migraine developed migraine-like attacks. Long-lasting vasodilation resulting in mechanically-induced sensitization of perivascular trigeminal afferents, as well as potassium (K^+) outflow and extracellular accumulation, resulting in chemically-induced sensitization of perivascular trigeminal afferents, have been proposed as mechanisms for BKCa channel activation-induced migraine attacks [100,101]. Several nonselective BKCa channel blockers, such as iberiotoxin and paxilline, have been developed, but they are not approved for clinical use due to the risk of severe on-target or off-target adverse events since BKCa channels are distributed throughout the body [102,103]. Therefore, selective blockers against $\beta 1$ or $\beta 4$ subunits, known to be expressed in migraine-related structures, are required in order to develop effective therapeutic molecules with good safety and tolerability profiles [104,105].

5. Purinergic system

The purinergic system is a complex signalling pathway involving the detection, release, and response to purine nucleotides and nucleosides, such as adenosine and ATP involved in various physiological and pathological processes [106,107]. Indeed, the purinergic system is involved in the

regulation of cardiovascular function, immune responses, gastrointestinal motility, renal function as well as in inflammation and pain perception [106,107]. Additionally, it plays a critical role in the regulation of neurotransmission in the central and peripheral nervous systems, where ATP and adenosine act as neuromodulators and participate in synaptic transmission and plasticity [108]. There are 19 purinergic receptors known to date, sub-divided into two main groups: adenosine receptors (P1 receptors) and purine/pyrimidine nucleotide (ATP, ADP, UTP, UDP) receptors (P2 receptors) [109,110]. More in depth, there are four subtypes of P1 receptors, namely A1, A2A, A2B, and A3, and fifteen P2 receptors represented by two families: P2X ionotropic ligand-gated ion channel receptors and P2Y metabotropic G protein-coupled receptors. ATP may act as a neurotransmitter in non-adrenergic non-cholinergic (NANC) nerves supplying gut and bladder or as a co-transmitter in sympathetic nerves (along with noradrenaline and neuropeptide Y), parasympathetic nerves (along with acetylcholine and vasoactive intestinal peptide), in enteric NANC inhibitory nerves (with nitric oxide and VIP), and in sensory-motor nerves (along with CGRP and substance P). Both groups of receptors, namely P1 and P2, have been explored as therapeutic targets for several conditions. Among these, the agonist adenosine (which binds to P1 receptors) is used to treat supraventricular tachycardia whereas antagonists of P2Y₁₂ receptor (mainly distributed on platelets), particularly clopidogrel and ticlopidine, are currently used as anti-platelet agents [111].

The involvement of purinergic signalling in migraine pathophysiology is strongly supported by the higher adenosine blood concentration in the course of migraine attacks, as well as by the ability of adenosine or dipyridamole (an adenosine uptake inhibitor) to induce headache or migraine-like attacks when administered intravenously in 78% of patients with migraine [112].

Interestingly, adenosine, through P1 receptors, can play a dual role in migraines since it could cause both sensitization of the trigeminovascular system and its inhibition [113]. More specifically, the stimulation of adenosine A1 receptors (expressed in the trigeminovascular system, including the trigeminal ganglion and trigeminal nucleus caudalis) inhibits trigeminovascular system by reducing neuronal firing from the trigeminal nucleus and decreasing the CGRP release. On the contrary, the stimulation of A2A and A2B receptors, located in vascular smooth muscle cells and in pre- and postsynaptic nerve terminals, causes dural vasodilation, leading to stimulation of the trigeminovascular system [113]. The proof of the concept comes from preclinical studies using selective A1 receptor agonists GR79236 and GR190178, able to inhibit trigeminovascular system by acting directly on the trigeminal nucleus and inhibiting the release of CGRP, in the absence of vasoconstriction [114]. Unfortunately, these molecules due to their off target effects on heart and autonomic nerves frequently induce bradycardia and hypotension making this approach not affordable in clinical practice.

On the other hand, P1 and P2 receptors, widely expressed in the CNS, particularly on the neurons and glial cells as well as on the smooth muscles and endothelium in the vascular system, seem to be similarly involved in migraine pathophysiology [112]. In particular, the activation of P2X receptors on smooth muscles by ATP (along with noradrenaline as co-transmitter) induces vasoconstriction being released by perivascular sympathetic nerves and damaged endothelial cells. Furthermore, ATP activates the P2X and P2Y receptors on the endothelial cells, which release endothelium-derived relaxing factor (EDRF) into the blood, leading to vasodilation and resulting in reactive hyperemia and pain. Moreover, P2Y₁₃ and P2X₃ receptors are expressed also in both human trigeminal ganglion and middle meningeal artery [115]. The administration of an agonist of P2Y₁₃ receptors (e.g. ADP β S) can cause middle meningeal artery contraction in vitro, reduced dural artery vasodilation following periarterial electrical stimulation in vivo, and reduction of CGRP release from both the dura and the trigeminal ganglion in situ [115]. On the other hand, the administration of an agonist of P2X₃ receptors (e.g. abmetATP) causes both CGRP release and middle meningeal artery dilation, making ATP-gated P2X₃ receptor antagonists promising candidates for antimigraine drug development such as AF-219 and A-317491 characterized by favourable pharmacodynamic and pharmacokinetic properties worthwhile for further exploration in clinical trials [116,117]. However,

the complexity of the purinergic signalling system and the lack of suitable animal models pose limitations in translating this research into clinical applications [112].

6. Opioid system

The opioid system plays a central role in pain perception and modulation but also in mood and the sense of well-being [118]. There are four major subtypes of opioid receptors – μ , δ , and κ -opioid receptors, and opioid receptor-like 1 (ORL-1)/nociception receptor [119]. Several endogenous substances exert their effect on these receptors. Among these, enkephalins are endogenous ligands with high affinity for the δ receptor, whereas endorphins preferentially activate the μ receptor, and dynorphins preferentially activate the κ -receptor. Herein, just for sake of completeness, we cite opioid analgesics that are μ -opioid agonists. Indeed, data on their efficacy in migraine are contradictory and they are associated with an increased risk of tolerance, physical dependence, and addiction although they continue to be prescribed extensively for acute migraine treatment in some parts of the world, particularly in the United State [120,121].

6.1. δ -Opioid Receptors

The δ -opioid receptors are widely expressed in brain regions involved in pain processing, such as the dorsal root and trigeminal ganglia, as well as the spinal cord [122]. However, unlike μ -receptors, their density is relatively low in nociceptive circuits of the midbrain and brainstem. In contrast, δ -opioid receptors are highly expressed in brain regions involved in processing the emotional contents of pain experience and mood regulation, including limbic forebrain structures, striatum, hippocampus, hypothalamus, and neuroendocrine system [123,124].

Preclinical studies in mice have shown that δ agonists inhibit mechanical and thermal allodynia induced by nitroglycerin (NTG) [125,126]. Indeed, mice lacking δ -opioid receptors show minimal modifications in acute pain threshold but exhibit significantly increased neuropathic and inflammatory pain [127,128]. Similarly, δ agonists have been found to effectively reduce behaviours that occur in response to persistent evoked pain [129]. Altogether, these findings suggest that, unlike μ receptors, δ -opioid receptors have limited involvement in acute pain.

There are converging evidences that δ -opioid receptors are implicated in anxiety, mood, and overall well-being as demonstrated by the fact that genetic deletion of the δ -opioid receptors or preproenkephalins results in increased levels of anxiety and depressive-like behaviours in animal models [130–132]. Similarly, pharmacological inhibition of δ -opioid receptors increases anxiety behaviours, which can be reversed by the δ -receptor agonist SNC80 [133].

Although, as abovementioned, δ -opioid receptors have only a partial role in acute pain, δ agonists have demonstrated efficacy in both acute and chronic models of migraine-associated allodynia [134]. Indeed, δ -agonists (e.g. SNC80, ARM390, and JNJ20788560) inhibit NTG-evoked mechanical hyperalgesia and SNC80 abolishes conditioned place aversion in mice and cortical spreading depression in response to continuous application of KCl in rodents [125]. Additionally, δ -opioid receptor agonists have been reported to inhibit the release of CGRP from activated trigeminal neurons [135]. Importantly, repeated treatment with SNC80 does not induce medication-overuse headache or opioid-induced hyperalgesia, in contrast to what happens administering morphine or sumatriptan, suggesting a lower potential for abuse using δ -agonists compared to μ -receptor agonists [136].

Since δ -opioid receptors are highly expressed in both the peripheral and CNS, it is unclear which sites regulate therapeutic effects on migraine. However, a recent study using a δ -opioid receptor knockout mice (e.g. for Nav1.8), which express about 50-70% less δ -opioid receptor in neurons of the dorsal root ganglia (considering that Nav1.8 is expressed in over 90% of peripheral nociceptors and mechanosensors), revealed that the anti-allodynic effect of SNC80 in the NTG model of migraine was only slightly reduced [137]. Nevertheless, the cephalic effects of SNC80 remained intact, as it continued to inhibit conditioned place aversion associated with NTG and decrease cortical spreading depression. These results suggest that the anti-migraine effects of δ agonists mainly occur in the CNS,

indicating that brain-penetrant δ agonists would be more effective in treating migraine, although the activation and "functionalization" of the receptors are necessarily required.

In conclusion, based on their distribution in migraine-related structures in the nervous system and preclinical evidences, the involvement of δ -opioid receptors in migraine is undeniable and, considering the low abuse potential, they can certainly represent a target for migraine therapies [138]. In this regard, a δ agonist designed for migraine treatment (i.e. TRV250) has completed a Phase I clinical trial and has shown high safety and tolerability [139,140].

6.2. κ -Opioid Receptors

The κ -opioid receptors are widely expressed in structures involved in the modulation of reward, mood states, and cognitive function, such as the ventral tegmental area, nucleus accumbens, prefrontal cortex, hippocampus, striatum, amygdala, locus coeruleus, substantia nigra, dorsal raphe nucleus, and hypothalamus [141,142]. Therefore, κ -opioid receptors have recently been identified as a novel putative therapeutic target for the treatment of stress-related mood disorders, including anxiety, depression, and drug seeking [143]. Based on these observations, it has been hypothesized that κ -opioid receptors antagonists may serve as effective preventive therapies for stress-related migraine, as well as in patients with medication overuse headache.

Interestingly, a very recent study has demonstrated that systemic administration of a κ -opioid receptors agonist in rodents provoked behaviours such as increased thirst and urination, which are consistent with clinically observed premonitory symptoms of migraine [144]. This finding suggests that targeting the hypothalamic κ -opioid receptors could enable early intervention for preventive treatment, even before the headache phase. In line with this hypothesis, it has been found that κ -opioid receptors blockade prevented both from stress-induced allodynia and increased plasma CGRP in rats chronically treated with sumatriptan as a model of medication overuse headache (making them hypersensitive to bright light stress and producing an increase in plasma CGRP leading to cephalic and peripheral allodynia) [145].

Moreover, a novel κ -opioid receptors antagonist, CERC-501 (formerly known as LY2456302) is currently in clinical trials for mood and anxiety disorders and has been shown to be safe and well-tolerated and selective orally available, reversible κ -opioid receptors antagonists are currently in development. Based on these early efficacy, safety and tolerability results, κ receptor antagonists may work as a promising therapy for migraine [146].

7. Transient receptor potential (TRP) channel family

The TRP channel superfamily comprises over 50 heterogeneous members, all of which serve as sensory transducers and contribute to various functions such as thermo- and osmo-sensation, vision, touch, and pain [147,148]. Within mammals, this superfamily is composed of six subfamilies and 28 members, which act as nonselective cation-permeable channels. TRPs share a similar structural framework, consisting of six transmembrane domains that assemble as homo- or hetero-tetramers. TRP channels exhibit non-selective permeability to Ca^{2+} , with different $\text{Ca}^{2+}/\text{Na}^{+}$ permeability ratios observed among the various members of the TRP superfamily. The six TRP subfamilies are classified as TRP canonical (TRPC), TRP melastatin (TRPM), TRP polycystin (TRPP), TRP mucolipin (TRPML), TRP vanilloid (TRPV), and TRP ankyrin (TRPA) channels [149]. Certain subfamilies encompass multiple members (e.g., the eight TRPM [TRPM1-8] receptors) or just one single member (i.e., the TRPA1 channel) and are influenced by an extensive array of endogenous and exogenous psychochemical stimuli, including intracellular mediators [148]. Several members of the TRP family are prominently expressed in distinct subsets of primary sensory neurons, where they play a role in detecting noxious physical and chemical stimuli. These channels, including TRPV1-4, TRPA1, and TRPM8, have collectively been referred to as thermo-TRP channels due to their ability to be activated by a broad range of temperatures, including noxious cold or heat [150]. Thermo-TRPs have been postulated to contribute to the transmission and modulation of nociceptive signals through multiple pathways, constituting the largest group of nociceptive ion channels involved in pain sensation [151].

Genetic and pharmacological studies have indicated that the TRPV1, TRPV4, and TRPA1 channels are major contributors in models of inflammatory and neuropathic pain. These receptors co-localize and are expressed in a subset of primary sensory neurons in the dorsal root ganglia, trigeminal ganglia, and vagal ganglia but also in hypothalamus (i.e. TRPV1 and TRPA1) as well as cortex, caudate nucleus, and amygdala (i.e. TRPA1). Moreover, TRPA1 has been identified also in cells of the Schwann cell/oligodendrocyte lineage, keratinocytes, vascular endothelial cells, and skin fibroblasts [152].

Several TRPs have been implicated in different pathways involved in migraine [153]. Specifically, TRPA1-positive (TRPA1+) terminals have been observed in both C-fibers and A δ -fibers of the trigeminal nucleus caudalis, frequently co-localized with CGRP, underpinning the release of neuropeptides from central and peripheral terminals of trigeminal nociceptors due to neuronal activation [154]. Meningeal vasodilation has been observed following the intranasal administration of TRPA1 agonists, while a selective TRPA1 receptor antagonist and a topical CGRP antagonist (CGRP8-37) have been shown to prevent the increase in blood flow [155]. In rats, a TRPA1 antagonist reduced mechanical allodynia caused by constriction of the infraorbital nerve and pain biomarkers triggered by NTG, likely inhibiting nitric oxide-mediated stimulation of TRPA1 in the soma of trigeminal nociceptors, with a release of reactive oxygen species (ROS) that, in turn, promotes a feed-forward ROS/TRPA1-dependent pathway that sustains allodynia [156–158]. Umbellulone, the primary component of *Umbellularia californica* (California bay laurel) and a TRPA1 agonist (able to induce nociceptive behaviour, nasal mucosa vasodilation, and the release of CGRP from meningeal tissue in rats), has been found to trigger migraine-like and cluster-like headaches in susceptible individuals [159]. Interestingly, in mice knock-out for TRPA1 all the observed responses to umbellulone were eliminated. These findings are in line with hypothesis that migraine-inducing substances like chlorine, cigarette smoke, formaldehyde, and others may exert their effects in humans by stimulating TRPA1, where act also certain analgesics commonly used for the treatment of migraine attacks. Similarly, pyrazolone derivatives (e.g. dipyrone, antipyrine, aminopyrine, and propyphenazone), used to provide acute relief in migraine attacks with an unclear mechanism of action, have been found to selectively antagonize TRPA1 both in vitro and in vivo, attenuating nociception and allodynia in animal models of neuropathic and inflammatory pain through a TRPA1-mediated mechanism (independently from prostaglandin production) [160,161].

During the past decade, significant progress has been made in the development of selective and potent TRPA1 antagonists and five of them have been evaluated in clinical trials for their potential use in the treatment of pain or asthma with different results. However, TRPA1 antagonists have not been specifically tested for migraine so far although a series of high affinity and selective TRPA1 antagonists are currently undergoing phase I and phase II clinical trials for various diseases characterized by pain component [162].

8. Glutamate

Glutamate is a neurotransmitter that exerts a wide range of complex effects within the CNS through its binding to several different receptors, each possessing distinct structural and functional properties [163]. These receptors can be broadly classified into two groups: ionotropic glutamate receptors, which act as channels, and metabotropic glutamate receptors, which are coupled to G proteins [164]. The ionotropic receptors can be further categorized into N-methyl-D-aspartate (NMDA), α -amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA), and 2-carboxy-3-carboxymethyl-4-isopropenylpyrrolidine (kainate) receptors. On the other hand, the metabotropic receptors are divided into three groups (groups I–III), situated mainly post-synaptically and activate phospholipase C (I) or pre-synaptically and activate adenylyl cyclase (II–III) [165]. Distinct locations are also related to their differential functions (release or inhibition of glutamate) and thus their effects on neuronal activity. Group I receptors predominantly exert pronociceptive effects, whereas those in groups II and III exhibit predominantly antinociceptive properties. Several preclinical and clinical evidences have reported the role of glutamate in migraine pathophysiology, and drugs acting on this

pathway have also been tested in these patients [166]. Indeed, kainate and glutamate receptor antagonists have demonstrated effectiveness in animal models of migraine, and the localization of glutamate receptors in regions associated with migraine pathophysiology, such as the trigeminal ganglion, trigeminal nucleus caudalis, and thalamus, further supports their potential involvement in migraine mechanisms [167].

Elevated levels of glutamate have been detected in patients with both episodic and chronic migraine, both during interictal and ictal period, in blood, saliva as well as in cerebrospinal fluid [168–173]. Accordingly, migraine preventive treatments with distinct pharmacodynamics have been reported to reduce plasma glutamate levels, although these findings (especially blood measurements) have not been consistently replicated, and, to date, there is no conclusive pharmacological clinical evidence demonstrating the effectiveness of specifically targeting glutamate, or its receptors, as migraine treatment [174].

Several anticonvulsant medications used in migraine, with different recommendations, are known to interfere with the glutamate pathway [175], but the target-specific perampanel, an antagonist of AMPA receptors, failed to demonstrate efficacy in a phase 2 randomized controlled trial with a placebo conducted in 206 patients with migraine (NCT00154063). However, targeting glutamate or its receptors represents a therapeutic challenge due to their essential role in the normal functioning of the nervous system, which makes it difficult to act on without causing on-target adverse effects.

9. Evidences related issues

Despite the large number of studies that have supported the identification of new potential targets for migraine prevention therapy over time, it should be emphasized that the related new drugs has also resulted in unexpected failures like in the latest striking case of the antibodies inhibiting PAC1 receptor of PACAP38 [41,176]. These results raise questions about the validity of migraine experimental models and study protocols from the preclinical models (in vitro and in vivo) through the to the provocation studies in humans.

Among the several issues, the choice of the biological fluid to be examined (the role of plasma dosage of neuropeptides is highly debated and it is not clear whether the serum levels adequately reflect the activation of trigemino-vascular system), the body district where to carry it out, the phase of the migraine cycle to obtain the sample and, above all, the extreme methodological variability in the techniques used for the dosages [177–180].

Another methodological issue that worth it to be discussed regards animal models of migraine that have been developed and exploited efficiently in the last decades, ranging from the manipulation of the mouse genome to produce animals with human disease-like, through sensitive immunohistochemical methods to vascular, neurovascular and electrophysiological studies. Nevertheless, if on one hand they lead to better understand potential migraine mechanisms as well as the mechanism of action of migraine treatments, on the other hand, animal experimental models cannot explain all the features of migraine complexity as experienced by humans, surely remaining a major hurdle to overcome [181–183]. Indeed, it is noteworthy that migraine is a complex neurological disorder that primarily affects humans and, in animal models we can only focus on “proxy” of migraine attacks (such as allodynia, light aversion, pain behavior) that strongly limit the translatability of findings from preclinical models to human migraine. Moreover, leaving aside the obvious anatomical, physiological, and pharmacological differences between animals and humans, preclinical models typically tend to rely on inducing migraine-like episodes through experimental manipulations, by administering chemical agents or electrical stimulations with detrimental consequences in the understanding natural history of migraine as well as the role of migraine triggers. The employment of animal models necessarily exclude specific pharmacological, cognitive and psychological elements (such as placebo or nocebo effects) which are known to play a critical role in migraine mechanisms as well as in the treatment response in humans.

Finally, beyond the above mentioned limitation of animal models, caution is mandatory in the interpretation of data from human provocative studies, due to the fact that despite the similarities

shared by provoked and spontaneous migraine attacks, substantial differences exist, mainly the source of migraine-inducing substances (exogenous vs. endogenous source) along with the absence of premonitory symptoms, underpinned by the different functional changes making the brain prone to an impending migraine attack [10,184]. In other terms, there is the high risk to focus, by inducing migraine-like attacks, on a snapshot of a very complex and multiphasic process.

10. Discussion

The increasing understanding of migraine pathophysiology strongly suggests that it is not only possible but also advisable to differentiate the pathophysiology of migraine as a condition of susceptibility of the CNS to certain trigger factors from the pathophysiology of migraine attacks as result of episodic activation of the trigeminal vascular system [185].

Despite the highly variable nature of trigger factors, all potentially affecting the CNS, they converge to activate the trigemino-vascular system through mechanisms that remain unclear. Over the past few decades, therapeutic strategies have progressively shifted away from CNS mechanisms of migraine towards the identification of peripheral targets [186]. Among these, CGRP, linking central trigemino-cervical system activation with peripheral processes like mast-cell degranulation and dilation of meningeal arteries, has been identified as the major contributor to migraine pain [187]. However, there is still approximately 40% of patients with migraine that have demonstrated an inadequate response to monoclonal antibodies and gepants targeting CGRP pathway, raising the question of CGRP as the sole or the main contributor to the peripheral mechanisms underlying migraine attacks [7]. The response came from provocative studies that, since the first demonstration of the nitric oxide donor ability (i.e. glyceryl trinitrate) to induce more severe headaches in patients with migraine than in healthy volunteers, have highlighted and validated the role of numerous other molecules in migraine attacks ignition [10,188] (See Figure 1 and Table 1 for further information).

In line with this view, we cannot exclude future development of diagnostic criteria based on the response to drugs targeting specific molecules in order to classify patients with migraine according to the prevalent pathway involved, as a proxy of molecular-based diagnosis [189]. In other terms, whether the mechanisms underlying the pathophysiology of migraine in non-responsive patients are similar to those of responsive patients or whether different migraine phenotypes exist, each involving specific pathophysiological pathways (e.g. CGRP-related migraine vs non-CGRP-related migraine), represent important avenues for ongoing and future research.

One could argue that targeting intracellular pathways shared by different neuropeptide signalling cascades might overcome the issue. Indeed, all the pathways activated by the different provocative molecules converge in a common intracellular downstream determinant where the second messengers cAMP or cGMP lead to the opening of potassium channels. The proof of the concept is in the ability of KATP channel opener to achieve a migraine induction rate of 100% in patients with migraine patently higher than the administration of other provocative molecules primarily acting on specific extracellular upstream determinants (such as neuropeptides, channels or receptors) [90].

Nevertheless, treatments targeting common intracellular downstream determinants although promising as preventive antimigraine treatment, may arise safety concerns regarding the risks of off-target adverse effects associated with inhibiting shared and convergent sub-cellular pathways.

On the other hand, considering migraine as a 'chronic brain disorder' and migraine attacks as its 'critical episodic manifestations' it is worth it considering whether drugs targeting extra-cerebral neuropeptides are treating the migraine disorder (in terms of brain predisposition to generate attacks) or merely inhibiting the peripheral compound of trigemino-vascular system whose ignition allows the clinical phenotype of migraine attacks, in a sort of peripheral "dam effect".

The latter concept may justify the recent observations of the frequency of migraine attacks worsening, after several months or years of treatment, when CGRP-mAbs are discontinued. In line with this interpretation, the findings from neurophysiological and neuroimaging studies, showing central effects of CGRP-mAbs treatment, may represent the epiphenomenon of the breakdown of the

bombardment of supramedullary brain structures involved in sensory, affective, endocrine, and autonomic functions by intracranial pain signals originating in the meninges [190–192].

Furthermore, in a speculative way, the peripheral “dam effect” (with no modulation of brain dys-excitability) raises an important point in the interpretation of migraine throughout the lens of allostatic disease (characterized by structural, microstructural, and functional changes) in which the “sickness behaviour” during migraine attacks serves as a major alarm system, evolved over time, aimed at restoring the energy homeostasis in brains burdened by the maladaptive overload [193]. Therefore, future pharmacological research should focus on therapeutic strategies that not only target peripheral mechanisms but also modulate central pathophysiological features of migraine brain. Probably, it is time to adopt a more holistic approach to the complexity of migraine, trying to address it as a comprehensive brain disorder with peripheral effectors in order to develop disease-modifying therapies while the primary future goal of treating underlying pathophysiological mechanisms rather than merely managing symptoms.

Funding: The APC of this article was partly covered by a grant from the Japanese Headache Society.

Acknowledgments: N.A.

Declaration of conflicting interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Silvestro has received speaker honoraria from Novartis, Teva and Lilly. Dr Iannone has received speaker honoraria from Teva and Lilly. Professor Tessitore has received speaker honoraria from Novartis, Schwarz Pharma/UCB, Lundbeck, Abbvie and Glaxo and serves as associate editor of European Journal of Neurology. Professor Tedeschi has received speaker honoraria from Sanofi-Aventis, Merck Serono, Bayer Schering Pharma, Novartis, Biogen-Dompe' AG, Teva and Lilly; has received funding for travel from Bayer Schering Pharma, Biogen-Dompe' AG, Merck Serono, Novartis and Sanofi Aventis; and serves as an associate editor of Neurological Sciences. Professor Russo has received speaker honoraria from Allergan, Lilly, Novartis, Biogen and Teva and serves as an associate editor of Frontiers in Neurology (Headache Medicine and Facial Pain session). The other authors have nothing to declare.

References

1. Steiner TJ, Stovner LJ, Jensen R, et al. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. *J Headache Pain*. 2020;21(1):137. Published 2020 Dec 2.
2. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. *Cephalalgia*. 2018;38(1):1-211.
3. Burch R. Preventive Migraine Treatment [published correction appears in *Continuum (Minneapolis)*. 2021 Oct 1;27(5):1494-1495]. *Continuum (Minneapolis)*. 2021;27(3):613-63.
4. Yuan D, Zhang Y, Li Q, et al. Factors Affecting Preventive Treatment Outcomes for Patients With Newly Diagnosed Chronic Migraine and Their Compliance With Treatment Recommendations in Chongqing Province, China: An Open-Label Prospective Study With Retrospective Baseline. *Front Neurol*. 2020;11:227. Published 2020 Apr 9.
5. Recober A. Pathophysiology of Migraine. *Continuum (Minneapolis)*. 2021;27(3):586-596.
6. Ashina M, Terwindt GM, Al-Karagholi MA, et al. Migraine: disease characterisation, biomarkers, and precision medicine. *Lancet*. 2021;397(10283):1496-1504.
7. Silvestro M, Orologio I, Siciliano M, et al. Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials. *Expert Opin Emerg Drugs*. 2023;28(2):79-96.
8. Sacco S, Braschinsky M, Ducros A, et al. European headache federation consensus on the definition of resistant and refractory migraine : Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). *J Headache Pain*. 2020;21(1):76. Published 2020 Jun 16
9. Silvestro M, Tessitore A, Scotto di Clemente F, et al. Refractory migraine profile in CGRP-monoclonal antibodies scenario. *Acta Neurol Scand*. 2021;144(3):325-333
10. Ashina M, Hansen JM, Á Dunga BO, et al. Human models of migraine - short-term pain for long-term gain. *Nat Rev Neurol*. 2017;13(12):713-724
11. Said S. I. (2011). VIP and PACAP. *Annals of the New York Academy of Sciences*, 1220(1), 1-7.

12. Arimura A, et al. (1989). Pituitary adenylate cyclase activating polypeptide (PACAP) is a potent stimulator of adenylyl cyclase in rat anterior pituitary gland. *Peptides*, 10(3), 541-544.
13. Vollesen ALH, Amin FM, Ashina M. Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine. *Neurotherapeutics*. 2018;15(2):371-376
14. Bourgault S, Vaudry D, Botia B, et al. Novel stable PACAP analogs with potent activity towards the PAC1 receptor. *Peptides*. 2008;29(6):919-932
15. Vaudry D, Gonzalez BJ, Basille M, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. *Pharmacol Rev*. 2000;52(2):269-324
16. Harmar AJ, Fahrenkrug J, Gozes I, et al. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. *Br J Pharmacol*. 2012;166(1):4-17
17. Arimura A. Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. *Jpn J Physiol*. 1998;48(5):301-331
18. Dickson L, Finlayson K. VPAC and PAC receptors: From ligands to function. *Pharmacol Ther*. 2009;121(3):294-316
19. Guo Z, Czerpaniak K, Zhang J, et al. Increase in trigeminal ganglion neurons that respond to both calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide in mouse models of chronic migraine and posttraumatic headache. *Pain*. 2021 May 1;162(5):1483-1499
20. Tuka B, Helyes Z, Markovics A, et al. Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. *Cephalalgia*. 2013;33(13):1085-1095
21. Zagami AS, Edvinsson L, Goadsby PJ. Pituitary adenylate cyclase activating polypeptide and migraine. *Ann Clin Transl Neurol*. 2014;1(12):1036-1040
22. Schytz HW, Birk S, Wienecke T, Kruuse C, et al. PACAP38 induces migraine-like attacks in patients with migraine without aura. *Brain*. 2009;132(Pt 1):16-25
23. Amin FM, Hougaard A, Schytz HW, et al. Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. *Brain*. 2014;137(Pt 3):779-794
24. Guo S, Vollesen AL, Hansen RD, et al. Part I: Pituitary adenylate cyclase-activating polypeptide-38 induced migraine-like attacks in patients with and without familial aggregation of migraine. *Cephalalgia*. 2017;37(2):125-135
25. Ghanizada H, Al-Karaghali MA, Arngrim N, et al. PACAP27 induces migraine-like attacks in migraine patients. *Cephalalgia*. 2020;40(1):57-67
26. Kuburas A, Russo AF. Shared and independent roles of CGRP and PACAP in migraine pathophysiology. *J Headache Pain*. 2023;24(1):34. Published 2023 Apr 3
27. Akerman S, Goadsby PJ. Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: Relevance to migraine. *Sci Transl Med*. 2015;7(308):308ra157
28. Amin FM, Schytz HW. Transport of the pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier: implications for migraine. *J Headache Pain*. 2018;19(1):35. Published 2018 May 21
29. Wienholtz NKF, Christensen CE, Zhang DG, et al. Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial. *Cephalalgia*. 2021;41(6):731-748
30. Ghanizada H, Al-Karaghali MA, Arngrim N, et al. Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache. *J Headache Pain*. 2020;21(1):19. Published 2020 Feb 24
31. Schmidt-Choudhury A, Furuta GT, Galli SJ, et al. Mast cells contribute to PACAP-induced dermal oedema in mice. *Regul Pept*. 1999;82(1-3):65-69
32. Vollesen LH, Guo S, Andersen MR, et al. Effect of the H1-antihistamine clemastine on PACAP38 induced migraine. *Cephalalgia*. 2019;39(5):597-607
33. Guo S, Vollesen ALH, Hansen YB, et al. Part II: biochemical changes after pituitary adenylate cyclase-activating polypeptide-38 infusion in migraine patients. *Cephalalgia*. 2017;37:136-147
34. Baun M, Pedersen MH, Olesen J, et al. Dural mast cell degranulation is a putative mechanism for headache induced by PACAP-38. *Cephalalgia*. 2012;32(4):337-345
35. Bhatt DK, Gupta S, Olesen J, et al. PACAP-38 infusion causes sustained vasodilation of the middle meningeal artery in the rat: possible involvement of mast cells. *Cephalalgia*. 2014;34(11):877-886
36. Pedersen SH, la Cour SH, Calloe K, et al. PACAP-38 and PACAP(6-38) Degranulate Rat Meningeal Mast Cells via the Orphan MrgB3-Receptor. *Front Cell Neurosci*. 2019;13:114. Published 2019 Mar 28

37. Ernstsens C, Christensen SL, Rasmussen RH, et al. The PACAP pathway is independent of CGRP in mouse models of migraine: possible new drug target? *Brain*. 2022;145(7):2450–2460
38. Guo S, Ernstsens C, Hay-Schmidt A, et al. PACAP signaling is not involved in GTN- and levromakalim-induced hypersensitivity in mouse models of migraine [published correction appears in *J Headache Pain*. 2023 Jun 19;24(1):73]. *J Headache Pain*. 2022;23(1):155
39. Kuburas A, Mason BN, Hing B, et al. PACAP Induces Light Aversion in Mice by an Inheritable Mechanism Independent of CGRP. *J Neurosci*. 2021;41(21):4697–4715
40. Rubio-Beltrán E, Correnti E, Deen M, et al. PACAP38 and PAC1 receptor blockade: a new target for headache?. *J Headache Pain*. 2018;19(1):64. Published 2018 Aug 7
41. Ashina M, Doležil D, Bonner JH, et al. A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. *Cephalalgia*. 2021;41(1):33–44
42. Ashina M. Targeting enkephalins and pituitary adenylate cyclase-activating polypeptide (PACAP) in migraine. *Brain*. 2022;145(8):2619–2620
43. Rasmussen NB, Deligianni C, Christensen CE, et al. The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study [published correction appears in *J Headache Pain*. 2023 Jun 19;24(1):74]. *J Headache Pain*. 2023;24(1):60. Published 2023 May 25
44. Domschke S, Domschke W, Bloom SR, et al. Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects. *Gut*. 1978;19(11):1049–1053
45. White CM, Ji S, Cai H, et al. Therapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders. *CNS Neurol Disord Drug Targets*. 2010;9(5):661–666
46. Csati A, Tajti J, Kuris A, et al. Distribution of vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, nitric oxide synthase, and their receptors in human and rat sphenopalatine ganglion. *Neuroscience*. 2012;202:158–168
47. Cernuda-Morollón E, Martínez-Camblor P, Alvarez R, et al. Increased VIP levels in peripheral blood outside migraine attacks as a potential biomarker of cranial parasympathetic activation in chronic migraine. *Cephalalgia*. 2015;35(4):310–316
48. Rahmann A, Wienecke T, Hansen JM, et al. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. *Cephalalgia*. 2008;28(3):226–236
49. Hansen JM, Sitarz J, Birk S, et al. Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. *Cephalalgia*. 2006;26(8):992–1003
50. Pellesi L, Al-Karaghali MA, Chaudhry BA, et al. Two-hour infusion of vasoactive intestinal polypeptide induces delayed headache and extracranial vasodilation in healthy volunteers. *Cephalalgia*. 2020;40(11):1212–1223
51. Pellesi L, Al-Karaghali MA, De Icco R, et al. Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches: A Randomized Clinical Trial. *JAMA Netw Open*. 2021;4(8):e2118543. Published 2021 Aug 2
52. Pellesi L, Al-Karaghali MA, De Icco R, et al. Plasma Levels of CGRP During a 2-h Infusion of VIP in Healthy Volunteers and Patients With Migraine: An Exploratory Study. *Front Neurol*. 2022;13:871176. Published 2022 Apr 1
53. Hu E, Hong FT, Aral J, et al. Discovery of Selective Pituitary Adenylate Cyclase 1 Receptor (PAC1R) Antagonist Peptides Potent in a Maxadilan/PACAP38-Induced Increase in Blood Flow Pharmacodynamic Model. *J Med Chem*. 2021;64(6):3427–3438
54. Moody TW, Ito T, Osefo N, et al. VIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies. *Curr Opin Endocrinol Diabetes Obes*. 2011 Feb;18(1):61–7
55. Kilinc E, Firat T, Tore F, et al. Vasoactive Intestinal peptide modulates c-Fos activity in the trigeminal nucleus and dura mater mast cells in sympathectomized rats. *J Neurosci Res*. 2015;93(4):644–650. doi:10.1002/jnr.23523
56. Hay DL, Garelja ML, Poyner DR, et al. Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25. *Br J Pharmacol*. 2018;175(1):3–17

57. Poyner DR, Sexton PM, Marshall I, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. *Pharmacol Rev.* 2002;54(2):233-246
58. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. *Endocr Rev.* 2000;21(2):138-167
59. Schönauer R, Els-Heindl S, Beck-Sickinger AG. Adrenomedullin - new perspectives of a potent peptide hormone. *J Pept Sci.* 2017;23(7-8):472-485
60. Béla K, Csongor AS, Deli MA, et al. Adrenomedullin and migraine. *Headache.* 2002;42(10):1064-1065
61. Juhl L, Petersen KA, Larsen EH, et al. The in vivo effect of adrenomedullin on rat dural and pial arteries. *Eur J Pharmacol.* 2006;538(1-3):101-107
62. Hayakawa H, Hirata Y, Kakoki M, et al. Role of nitric oxide-cGMP pathway in adrenomedullin-induced vasodilation in the rat. *Hypertension.* 1999;33(2):689-693.
63. Wong LY, Cheung BM, Li YY, et al. Adrenomedullin is both proinflammatory and antiinflammatory: its effects on gene expression and secretion of cytokines and macrophage migration inhibitory factor in NR8383 macrophage cell line. *Endocrinology.* 2005;146(3):1321-1327
64. Li FJ, Zheng SR, Wang DM. Adrenomedullin: an important participant in neurological diseases. *Neural Regen Res.* 2020 Jul;15(7):1199-1207
65. Huang H, Wang M, Hong Y. Intrathecal administration of adrenomedullin induces mechanical allodynia and neurochemical changes in spinal cord and DRG. *Neurosci Lett.* 2019;690:196-201
66. Sugimoto Y, Shiraiishi S, Yasuda T, et al. Intrathecal adrenomedullin modulates acute inflammatory pain in the rat formalin test. *Neurosci Lett.* 2013;552:146-150
67. Fernández AP, Serrano J, Martínez-Murillo R, et al. Lack of adrenomedullin in the central nervous system results in apparently paradoxical alterations on pain sensitivity. *Endocrinology.* 2010;151(10):4908-4915
68. Petersen KA, Birk S, Kitamura K, et al. Effect of adrenomedullin on the cerebral circulation: relevance to primary headache disorders. *Cephalalgia.* 2009;29(1):23-30
69. Ghanizada H, Iljazi A, Ashina H, et al. Nocebo response in human models of migraine: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled, two-way crossover trials in migraine without aura and healthy volunteers. *Cephalalgia.* 2021;41(1):99-111
70. Ghanizada H, Al-Karagholi MA, Arnglim N, et al. Effect of Adrenomedullin on Migraine-Like Attacks in Patients With Migraine: A Randomized Crossover Study. *Neurology.* 2021;96(20):e2488-e2499
71. Rees TA, Hendrikse ER, Hay DL, et al. Beyond CGRP: The calcitonin peptide family as targets for migraine and pain. *Br J Pharmacol.* 2022;179(3):381-399
72. Hay DL. Amylin. *Headache.* 2017;57 Suppl 2:89-96
73. Lutz TA. Pancreatic amylin as a centrally acting satiating hormone. *Curr Drug Targets.* 2005;6(2):181-189
74. Hollander P, Maggs DG, Ruggles JA, et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. *Obes Res.* 2004;12(4):661-668
75. Edvinsson L, Grell AS, Warfvinge K. Expression of the CGRP Family of Neuropeptides and their Receptors in the Trigeminal Ganglion. *J Mol Neurosci.* 2020;70(6):930-944
76. de Vries T, MaassenVanDenBrink A. CGRP-targeted antibodies in difficult-to-treat migraine. *Nat Rev Neurol.* 2019;15(12):688-689
77. Gebre-Medhin S, Mulder H, Zhang Y, et al. Reduced nociceptive behaviour in islet amyloid polypeptide (amylin) knockout mice. *Brain Res Mol Brain Res.* 1998;63(1):180-183
78. Rea BJ, Davison A, Ketcha MJ, et al. Automated detection of squint as a sensitive assay of sex-dependent calcitonin gene-related peptide and amylin-induced pain in mice. *Pain.* 2022;163(8):1511-1519
79. Garelja ML, Hay DL. A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene-related peptide and beyond. *Headache.* 2022;62(9):1093-1104
80. Khoshdel Z, Takhshid MA, Owji AA. Effects of intrathecal amylin on formalin-induced nociception and on cAMP accumulation in the rat embryonic spinal cells. *Neuropeptides.* 2016;57:95-100
81. Sibilica V, Pagani F, Lattuada N, et al. Amylin compared with calcitonin: competitive binding studies in rat brain and antinociceptive activity. *Brain Res.* 2000;854(1-2):79-84
82. Irimia P, Martínez-Valbuena I, Mínguez-Olaondo A, et al. Interictal amylin levels in chronic migraine patients: A case-control study. *Cephalalgia.* 2021;41(5):604-612

83. Ghanizada H, Al-Karagholi MA, Walker CS, et al. Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients. *Ann Neurol*. 2021;89(6):1157-1171
84. Hibino H, Inanobe A, Furutani K, et al. Inwardly rectifying potassium channels: their structure, function, and physiological roles. *Physiol Rev*. 2010;90(1):291-366
85. Akrouh A, Halcomb SE, Nichols CG, et al. Molecular biology of K(ATP) channels and implications for health and disease. *IUBMB Life*. 2009;61(10):971-978
86. Tinker A, Aziz Q, Li Y, et al. ATP-Sensitive Potassium Channels and Their Physiological and Pathophysiological Roles. *Compr Physiol*. 2018;8(4):1463-1511. Published 2018 Sep 14
87. Nichols CG. KATP channels as molecular sensors of cellular metabolism. *Nature*. 2006;440(7083):470-476
88. Seino S, Miki T. Physiological and pathophysiological roles of ATP-sensitive K⁺ channels. *Prog Biophys Mol Biol*. 2003;81(2):133-176
89. Jahangir A, Terzic A. K(ATP) channel therapeutics at the bedside. *J Mol Cell Cardiol*. 2005;39(1):99-112
90. Al-Karagholi MA, Hansen JM, Guo S, et al. Opening of ATP-sensitive potassium channels causes migraine attacks: a new target for the treatment of migraine. *Brain*. 2019;142(9):2644-2654
91. Al-Karagholi MA, Ghanizada H, Nielsen CAW, et al. Opening of ATP sensitive potassium channels causes migraine attacks with aura. *Brain*. 2021;144(8):2322-2332
92. Al-Karagholi MA, Ghanizada H, Kokoti L, et al. Effect of KATP channel blocker glibenclamide on levromakalim-induced headache. *Cephalalgia*. 2020;40(10):1045-1054
93. Gozalov A, Jansen-Olesen I, Klaerke D, et al. Role of K ATP channels in cephalic vasodilatation induced by calcitonin gene-related peptide, nitric oxide, and transcranial electrical stimulation in the rat. *Headache*. 2008;48(8):1202-1213
94. Coskun H, Elbahi FA, Al-Karagholi MA, et al. The Effect of K ATP Channel Blocker Glibenclamide on CGRP-Induced Headache and Hemodynamic in Healthy Volunteers. *Front Physiol*. 2021;12:652136. Published 2021 Jun 11
95. Kokoti L, Al-Karagholi MA, Elbahi FA, et al. Effect of KATP channel blocker glibenclamide on PACAP38-induced headache and hemodynamic. *Cephalalgia*. 2022;42(9):846-858
96. Meera P, Wallner M, Song M, et al. Large conductance voltage- and calcium-dependent K⁺ channel, a distinct member of voltage-dependent ion channels with seven N-terminal transmembrane segments (S0-S6), an extracellular N terminus, and an intracellular (S9-S10) C terminus. *Proc Natl Acad Sci U S A*. 1997;94(25):14066-14071
97. Ge L, Hoa NT, Wilson Z, et al. Big Potassium (BK) ion channels in biology, disease and possible targets for cancer immunotherapy. *Int Immunopharmacol*. 2014 Oct;22(2):427-43
98. Brenner R, Pérez GJ, Bonev AD, et al. Vasoregulation by the beta1 subunit of the calcium-activated potassium channel. *Nature*. 2000;407(6806):870-876
99. Knaus HG, Schwarzer C, Koch RO, et al. Distribution of high-conductance Ca(2+)-activated K⁺ channels in rat brain: targeting to axons and nerve terminals. *J Neurosci*. 1996;16(3):955-963
100. Al-Karagholi MA, Ghanizada H, Nielsen CAW, et al. Opening of BKCa channels alters cerebral hemodynamic and causes headache in healthy volunteers. *Cephalalgia*. 2020;40(11):1145-1154
101. Al-Karagholi MA, Ghanizada H, Waldorff Nielsen CA, et al. Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine. *Pain*. 2021;162(10):2512-2520
102. Storer RJ, Immke DC, Goadsby PJ. Large conductance calcium-activated potassium channels (BKCa) modulate trigeminovascular nociceptive transmission. *Cephalalgia*. 2009;29(12):1242-1258
103. Zhou Y, Xia XM, Lingle CJ. The functionally relevant site for paxilline inhibition of BK channels. *Proc Natl Acad Sci U S A*. 2020;117(2):1021-1026
104. Poulsen AN, Wulf H, Hay-Schmidt A, et al. Differential expression of BK channel isoforms and beta-subunits in rat neuro-vascular tissues. *Biochim Biophys Acta*. 2009;1788(2):380-389
105. Al-Karagholi MA, Hakbilen CC, Ashina M. The role of high-conductance calcium-activated potassium channel in headache and migraine pathophysiology. *Basic Clin Pharmacol Toxicol*. 2022;131(5):347-354
106. Huang Z, Xie N, Illes P, et al. From purines to purinergic signalling: molecular functions and human diseases. *Signal Transduct Target Ther*. 2021 Apr 28;6(1):162
107. Antonioli L, Colucci R, Pellegrini C, et al. The role of purinergic pathways in the pathophysiology of gut diseases: pharmacological modulation and potential therapeutic applications. *Pharmacol Ther*. 2013;139(2):157-188

108. Cotrina ML, Lin JH, López-García JC, et al. ATP-mediated glia signaling. *J Neurosci*. 2000;20(8):2835-2844
109. Burnstock G. Purine and pyrimidine receptors. *Cell Mol Life Sci*. 2007;64(12):1471-1483
110. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. *Pharmacol Rev*. 1998;50(3):413-492
111. Gachet C. ADP receptors of platelets and their inhibition. *Thromb Haemost*. 2001;86(1):222-232
112. Cieślak M, Czarnecka J, Roszek K, et al. The role of purinergic signaling in the etiology of migraine and novel antimigraine treatment. *Purinergic Signal*. 2015;11(3):307-316
113. Thuraiah J, Kokoti L, Al-Karaghali MA, et al. Involvement of adenosine signaling pathway in migraine pathophysiology: a systematic review of preclinical studies. *J Headache Pain*. 2022;23(1):43. Published 2022 Apr 5
114. Goadsby PJ, Hoskin KL, Storer RJ, et al. Adenosine A1 receptor agonists inhibit trigeminovascular nociceptive transmission. *Brain*. 2002;125(Pt 6):1392-1401
115. Haanes KA, Labastida-Ramírez A, Blixt FW, et al. Exploration of purinergic receptors as potential anti-migraine targets using established pre-clinical migraine models. *Cephalalgia*. 2019;39(11):1421-1434
116. Giniatullin R, Nistri A. Role of ATP in migraine mechanisms: focus on P2X3 receptors. *J Headache Pain*. 2023;24(1):1. Published 2023 Jan 3
117. Jarvis MF, Bianchi B, Uchic JT, et al. [3H]A-317491, a novel high-affinity non-nucleotide antagonist that specifically labels human P2X2/3 and P2X3 receptors. *J Pharmacol Exp Ther*. 2004;310(1):407-416
118. Nummenmaa L, Tuominen L. Opioid system and human emotions. *Br J Pharmacol*. 2018;175(14):2737-2749
119. Shang Y, Filizola M. Opioid receptors: Structural and mechanistic insights into pharmacology and signaling. *Eur J Pharmacol*. 2015;763(Pt B):206-213
120. VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. *JAMA*. 2021;325(23):2357-2369
121. Bigal ME, Lipton RB. Excessive opioid use and the development of chronic migraine. *Pain*. 2009;142(3):179-182
122. Pradhan AA, Befort K, Nozaki C, et al. The delta opioid receptor: an evolving target for the treatment of brain disorders. *Trends Pharmacol Sci*. 2011;32(10):581-590
123. Lutz PE, Kieffer BL. Opioid receptors: distinct roles in mood disorders. *Trends Neurosci*. 2013;36(3):195-206
124. Le Merrer J, Becker JA, Befort K, et al. Reward processing by the opioid system in the brain. *Physiol Rev*. 2009;89(4):1379-1412
125. Pradhan AA, Smith ML, Zyuzin J, et al. δ -Opioid receptor agonists inhibit migraine-related hyperalgesia, aversive state and cortical spreading depression in mice. *Br J Pharmacol*. 2014;171(9):2375-2384
126. Dripps IJ, Boyer BT, Neubig RR, et al. Role of signalling molecules in behaviours mediated by the δ opioid receptor agonist SNC80. *Br J Pharmacol*. 2018;175(6):891-901
127. Gavériaux-Ruff C, Karchewski LA, Hever X, et al. Inflammatory pain is enhanced in delta opioid receptor-knockout mice. *Eur J Neurosci*. 2008;27(10):2558-2567
128. Gavériaux-Ruff C, Nozaki C, Nadal X, et al. Genetic ablation of delta opioid receptors in nociceptive sensory neurons increases chronic pain and abolishes opioid analgesia. *Pain*. 2011;152(6):1238-1248
129. Vicente-Sanchez A, Segura L, Pradhan AA. The delta opioid receptor tool box. *Neuroscience*. 2016;338:145-159
130. Filliol D, Ghazizadeh S, Chluba J, et al. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. *Nat Genet*. 2000;25(2):195-200
131. König M, Zimmer AM, Steiner H, et al. Pain responses, anxiety and aggression in mice deficient in preproenkephalin. *Nature*. 1996;383(6600):535-538
132. Ragnauth A, Schuller A, Morgan M, et al. Female preproenkephalin-knockout mice display altered emotional responses. *Proc Natl Acad Sci U S A*. 2001;98(4):1958-1963
133. Saitoh A, Kimura Y, Suzuki T, et al. Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents. *J Pharmacol Sci*. 2004;95(3):374-380
134. Moye LS, Tipton AF, Dripps I, et al. Delta opioid receptor agonists are effective for multiple types of headache disorders. *Neuropharmacology*. 2019;148:77-86
135. Patwardhan AM, Berg KA, Akopain AN, et al. Bradykinin-induced functional competence and trafficking of the delta-opioid receptor in trigeminal nociceptors. *J Neurosci*. 2005;25(39):8825-8832

136. Do Carmo GP, Folk JE, Rice KC, et al. The selective non-peptidic delta opioid agonist SNC80 does not facilitate intracranial self-stimulation in rats. *Eur J Pharmacol.* 2009;604(1-3):58-65
137. Dripps IJ, Bertels Z, Moye LS, et al. Forebrain delta opioid receptors regulate the response of delta agonist in models of migraine and opioid-induced hyperalgesia. *Sci Rep.* 2020;10(1):17629. Published 2020 Oct 19
138. Charles A, Pradhan AA. Delta-opioid receptors as targets for migraine therapy. *Curr Opin Neurol.* 2016;29(3):314-319
139. Bertels Z, Pradhan AAA. Emerging Treatment Targets for Migraine and Other Headaches. *Headache.* 2019;59 Suppl 2(Suppl 2):50-65
140. Fossler MJ, Schmith V, Greene SA, et al. A Phase I, Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects. *CNS Drugs.* 2020;34(8):853-865
141. Mansour A, Khachaturian H, Lewis ME, et al. Anatomy of CNS opioid receptors. *Trends Neurosci.* 1988;11(7):308-314
142. Peng J, Sarkar S, Chang SL. Opioid receptor expression in human brain and peripheral tissues using absolute quantitative real-time RT-PCR. *Drug Alcohol Depend.* 2012;124(3):223-228
143. Carlezon WA Jr, Krystal AD. Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials. *Depress Anxiety.* 2016;33(10):895-906
144. Kopruszinski CM, Vizin R, Watanabe M, et al. Exploring the neurobiology of the premonitory phase of migraine preclinically - a role for hypothalamic kappa opioid receptors?. *J Headache Pain.* 2022;23(1):126. Published 2022 Sep 30
145. Xie JY, De Felice M, Kopruszinski CM, et al. Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention. *Cephalalgia.* 2017;37(8):780-794
146. Lowe SL, Wong CJ, Witcher J, et al. Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects. *J Clin Pharmacol.* 2014;54(9):968-978
147. Ramsey IS, Delling M, Clapham DE. An introduction to TRP channels. *Annu Rev Physiol.* 2006;68:619-647
148. Nilius B, Owsianik G, Voets T, et al. Transient receptor potential cation channels in disease. *Physiol Rev.* 2007;87(1):165-217
149. Koivisto AP, Belvisi MG, Gaudet R, et al. Advances in TRP channel drug discovery: from target validation to clinical studies. *Nat Rev Drug Discov.* 2022;21(1):41-59
150. Patapoutian A, Peier AM, Story GM, et al. ThermoTRP channels and beyond: mechanisms of temperature sensation [published correction appears in *Nat Rev Neurosci.* 2003 Aug;4(8):691]. *Nat Rev Neurosci.* 2003;4(7):529-539
151. Clapham DE, Runnels LW, Strübing C. The TRP ion channel family. *Nat Rev Neurosci.* 2001;2(6):387-396
152. Maglie R, Souza Monteiro de Araujo D, Antiga E, et al. The Role of TRPA1 in Skin Physiology and Pathology. *Int J Mol Sci.* 2021;22(6):3065. Published 2021 Mar 17
153. Iannone LF, De Logu F, Geppetti P, et al. The role of TRP ion channels in migraine and headache. *Neurosci Lett.* 2022;768:136380
154. Edvinsson L, Ekman R, Jansen I, et al. Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. *J Cereb Blood Flow Metab.* 1987;7(6):720-728
155. Kunkler PE, Ballard CJ, Oxford GS, et al. TRPA1 receptors mediate environmental irritant-induced meningeal vasodilatation. *Pain.* 2011;152(1):38-44
156. Ferrari LF, Levine JD, Green PG. Mechanisms mediating nitroglycerin-induced delayed-onset hyperalgesia in the rat. *Neuroscience.* 2016;317:121-129
157. Bates EA, Nikai T, Brennan KC, et al. Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in mice. *Cephalalgia.* 2010;30(2):170-178
158. Demartini C, Greco R, Zanaboni AM, et al. Antagonism of Transient Receptor Potential Ankyrin Type-1 Channels as a Potential Target for the Treatment of Trigeminal Neuropathic Pain: Study in an Animal Model. *Int J Mol Sci.* 2018;19(11):3320. Published 2018 Oct 25
159. Nassini R, Materazzi S, Vriens J, et al. The 'headache tree' via umbellulone and TRPA1 activates the trigeminovascular system. *Brain.* 2012;135(Pt 2):376-390
160. Ramacciotti AS, Soares BG, Atallah AN. Dipyrone for acute primary headaches. *Cochrane Database Syst Rev.* 2007;(2):CD004842. Published 2007 Apr 18

161. Nassini R, Fusi C, Materazzi S, et al. The TRPA1 channel mediates the analgesic action of dipyrone and pyrazolone derivatives. *Br J Pharmacol*. 2015;172(13):3397-3411
162. Chen H, Terrett JA. Transient receptor potential ankyrin 1 (TRPA1) antagonists: a patent review (2015-2019). *Expert Opin Ther Pat*. 2020;30(9):643-657
163. Zhou Y, Danbolt NC. Glutamate as a neurotransmitter in the healthy brain. *J Neural Transm (Vienna)*. 2014 Aug;121(8):799-817
164. Kew JN, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology [published correction appears in *Psychopharmacology (Berl)*. 2005 Oct;182(2):320]. *Psychopharmacology (Berl)*. 2005;179(1):4-29
165. Traynelis SF, Wollmuth LP, McBain CJ, et al. Glutamate receptor ion channels: structure, regulation, and function [published correction appears in *Pharmacol Rev*. 2014 Oct;66(4):1141]. *Pharmacol Rev*. 2010;62(3):405-496
166. Hoffmann J, Charles A. Glutamate and Its Receptors as Therapeutic Targets for Migraine. *Neurotherapeutics*. 2018;15(2):361-370
167. Chan K, MaassenVanDenBrink A. Glutamate receptor antagonists in the management of migraine. *Drugs*. 2014;74(11):1165-1176
168. Nam JH, Lee HS, Kim J, Kim J, et al. Salivary glutamate is elevated in individuals with chronic migraine. *Cephalalgia*. 2018;38(8):1485-1492
169. Rajda C, Tajti J, Komoróczy R, et al. Amino acids in the saliva of patients with migraine. *Headache*. 1999;39(9):644-649
170. Martínez F, Castillo J, Rodríguez JR, et al. Neuroexcitatory amino acid levels in plasma and cerebrospinal fluid during migraine attacks. *Cephalalgia*. 1993;13(2):89-93
171. Ferrari MD, Odink J, Bos KD, et al. Neuroexcitatory plasma amino acids are elevated in migraine. *Neurology*. 1990;40(10):1582-1586
172. Campos F, Sobrino T, Pérez-Mato M, et al. Glutamate oxaloacetate transaminase: a new key in the dysregulation of glutamate in migraine patients. *Cephalalgia*. 2013;33(14):1148-1154
173. Peres MF, Zukerman E, Senne Soares CA, et al. Cerebrospinal fluid glutamate levels in chronic migraine. *Cephalalgia*. 2004;24(9):735-739
174. Ferrari A, Spaccapelo L, Pinetti D, et al. Effective prophylactic treatments of migraine lower plasma glutamate levels. *Cephalalgia*. 2009;29(4):423-429
175. Rollo E, Romozzi M, Vollono C, et al. Antiseizure Medications for the Prophylaxis of Migraine during the Anti- CGRP Drugs Era. *Curr Neuroparmacol*. 2023;21(8):1767-1785
176. Haanes KA, Edvinsson L. Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets. *CNS Drugs*. 2019;33(6):525-537
177. Lee MJ, Lee SY, Cho S, et al. Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal. *J Headache Pain*. 2018;19(1):53
178. Pérez-Pereda S, Toriello-Suárez M, Oejo-Vinyals G, et al. Serum CGRP, VIP, and PACAP usefulness in migraine: a case-control study in chronic migraine patients in real clinical practice. *Mol Biol Rep*. 2020;47(9):7125-7138
179. Kamm K, Straube A, Ruscheweyh R. Calcitonin gene-related peptide levels in tear fluid are elevated in migraine patients compared to healthy controls. *Cephalalgia*. 2019;39(12):1535-1543
180. Ferroni P, Barbanti P, Spila A, et al. Circulating Biomarkers in Migraine: New Opportunities for Precision Medicine. *Curr Med Chem*. 2019;26(34):6191-6206
181. Charles A. Advances in the basic and clinical science of migraine. *Ann Neurol*. 2009;65(5):491-498
182. Olesen J, Jansen-Olesen I. Towards a reliable animal model of migraine. *Cephalalgia*. 2012;32(7):578-580
183. Bergerot A, Holland PR, Akerman S, et al. Animal models of migraine: looking at the component parts of a complex disorder. *Eur J Neurosci*. 2006;24(6):1517-1534
184. Ashina H, Christensen RH, Ashina M. Provoked versus spontaneous migraine attacks: pathophysiological similarities and differences. *J Headache Pain*. 2022;23(1):87. Published 2022 Jul 23
185. Charles A. The pathophysiology of migraine: implications for clinical management. *Lancet Neurol*. 2018;17(2):174-182
186. Al-Hassany L, Boucherie DM, Creaney H, et al. Future targets for migraine treatment beyond CGRP. *J Headache Pain*. 2023;24(1):76. Published 2023 Jun 28

187. Edvinsson L. CGRP-receptor antagonism in migraine treatment. *Lancet*. 2008;372(9656):2089-2090
188. Bhakta M, Vuong T, Taura T, et al. Migraine therapeutics differentially modulate the CGRP pathway. *Cephalalgia*. 2021;41(5):499-514
189. Shibata Y. Migraine Pathophysiology Revisited: Proposal of a New Molecular Theory of Migraine Pathophysiology and Headache Diagnostic Criteria. *Int J Mol Sci*. 2022;23(21):13002. Published 2022 Oct 27
190. de Tommaso M, La Rocca M, Quitadamo SG, et al. Central effects of galcanezumab in migraine: a pilot study on Steady State Visual Evoked Potentials and occipital hemodynamic response in migraine patients. *J Headache Pain*. 2022;23(1):52. Published 2022 Apr 29. doi:10.1186/s10194-022-01421-z
191. Ziegeler C, Mehnert J, Asmussen K et al. Central effects of erenumab in migraine patients: An event-related functional imaging study. *Neurology*. 2020;95(20):e2794-e2802.
192. Nosedá R, Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, CSD, sensitization and modulation of pain. *Pain*. 2013 Dec;154 Suppl 1:10.1016/j.pain.2013.07.021. doi: 10.1016/j.pain.2013.07.021. PMID: 24347803; PMCID: PMC3858400
193. Maleki N, Becerra L, Borsook D. Migraine: maladaptive brain responses to stress. *Headache*. 2012;52 Suppl 2(Suppl 2):102-106. doi:10.1111/j.1526-4610.2012.02241.x

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.